Access earnings results, analyst expectations, report, slides, earnings call, and transcript.

The earnings call reveals several negative indicators: reduced revenue guidance, declining gross profit margins, and increased operating expenses. The Q&A section shows management's reluctance to provide specific guidance for 2026, adding uncertainty. Despite some positives like new product launches and a stock repurchase program, the overall sentiment is negative due to financial declines and management changes. These factors, combined with competitive pressures and lack of clear future direction, suggest a likely negative stock price movement.
The earnings call presents a mixed outlook. While there are positive elements such as expected revenue growth from acquisitions and market expansion opportunities, there are concerns regarding declining EPS guidance and pricing pressures on PYLARIFY. The Q&A highlighted uncertainties in contract dynamics and market competition. Despite potential growth in Alzheimer's diagnostics, the flat PYLARIFY growth and the impact of acquisitions on EPS dilute the overall sentiment. The absence of clear guidance on certain aspects further adds to the neutral stance.
The earnings call presents mixed signals. While strategic partnerships and other revenue increased significantly, core areas like PYLARIFY and Precision Diagnostics remained flat. The company faces competitive challenges and has reduced its EPS guidance, indicating potential short-term struggles. However, optimistic long-term growth potential in the Alzheimer's diagnostic market and strategic transactions could offset these concerns. The market reaction is likely to be neutral, reflecting the balance between short-term challenges and long-term optimism.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.